Adocia Announces Its Financial Calendar for 2014

Regulatory News:

ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 - ADOC), a biotechnology company specialized in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today announces today its financial calendar for 2014.

Adocia is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company’s website (www.adocia.com). All corporate information on the company such as its financial statements or its corporate presentations is available on the company’s website, in the Investor’s section, « Regulated Information ».

About Adocia:

To be a global leader for the formulation of therapeutic proteins
Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins.
Adocia is specialized in insulin therapy and the treatment of the diabetic foot, one of the main complications of diabetes. Worldwide, more than 366 million individuals are currently suffering from diabetes (with a forecast of 552 million individuals by 2030, i.e. a 51% increase, reaching 70% in emerging countries). 15% of these patients will develop a foot ulcer during their lifetime. The markets targeted by Adocia represent more than USD20 billion (USD17 billion for insulin therapy and USD3 billion for diabetic foot ulcer healing).
Through its BioChaperone® state-of-the-art technological platform, Adocia intends to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public.
Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin, on the formulation of a ultra-fast acting insulin analog and obtained promising phase I/II results on a diabetic foot ulcer-healing product. Furthermore, Adocia is developing a unique combination of glargine with a fast-acting insulin, for an optimal insulin therapy with one single product.
Based on its experience and recognized know-how, Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies.

To fight cancer by a better targeting of anti-tumoral agents
End of 2013, Adocia signed an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors. This nanotechnology, called DriveIn^®, is remarkably efficient in carrying active molecules and delivering them within solid tumors. This new platform in nanotechnology for applications is an exceptional opportunity to fight cancer by improving the efficacy of already approved treatments
Adocia intends to develop proprietary products based on doxorubicin and docetaxel, two of the most used anti-tumoral treatments, which could greatly benefit from an enhanced intra-cellular delivery. On the other hand, Adocia will propose the DriveIn technology to pharmaceutical companies to optimize the efficacy of their own proprietary molecules.

"Innovative medicine for everyone, everywhere”
Adocia’s therapeutic innovations aim at bringing solutions to a profoundly changing global pharmaceutical and economic context, characterized in particular by the increased prevalence and impact of the targeted pathologies, population growth and ageing, the need to control public health expenditures and increasing demand from emerging countries.
Adocia is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241, mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP) and its share included in the Next Biotech index.
For more information: www.adocia.com

Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the "Risk Factors” section of the Reference Document registered by the Autorité des marchés financiers on April 25, 2013 under number R13-017 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.